Biotherapeutics Cell Line Development Market

1. Biotherapeutics Cell Line Development Market to Reach US$99.84 mn by 2022, Rising Demand for Monoclonal Antibodies Fuels Growth According to a new market report published by Transparency Market Research “Biotherapeutics Cell Line Development Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2022”,the global biotherapeutics cell line development market was valued at US$56.03 mn in 2014 and is anticipated to expand at a CAGR of 7.5% from 2015 to 2022 to reach US$99.84 mn by 2022. The demand for biotherapeutics is continuously increasing, because many biopharmaceutical drugs are reaching later stage clinical trials. Most biotherapeutic drugs are recombinant monoclonal antibodies which are widely produced in mammalian cell lines because of the need for post-translational modifications that should be alike or at least similar to those obtained in humans. Thus, there is an increase in the market for cell line development. Moreover, advancements in upstream processing technologies have led to improvement in speed and efficiency of generating robust and highly productive cell line for large scale production of protein therapeutics and has propelled the market for cell line development. Get a Sample Copy of Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8272 Increasing proportion of geriatric population across the globe and prevalence of various diseases among them are the major factors driving the market. Moreover, increase in the demand for monoclonal antibodies across the globe is another factor driving the market for biotherapeutics cell line development. The global biotherapeutics cell line development market is segmented by process, by cell line development option and by geography. The market by process segment has been sub-segmented as transfection and single cell cloning. The single cell cloning market is further segmented by method as manual limited dilution cloning, FACS, ClonePix and Others. The market by CLD option is segmented as In-house, outsource, hybrid and do-it-yourself. The ClonePix accounted for the largest market share of 37.4% in 2014. Due to high throughput nature of the ClonePix, this method is widely adopted and the market is further expected to grow in the coming years. Due to the trend of outsourcing in this market, the market for outsourcing is expected to grow at the highest rate in coming years. Major players in this market are Beckton Dickinson & Company (U.S.), Beckman Coulter (U.S.), Boehringer Ingelheim Group (Germany), Catalent Inc. (U.S.), CMC Biologics A/S (Denmark), Lonza

2. Group Ltd. (Switzerland), EMD Millipore (U.S.), Partec (Sysmex Corporation) (Japan), ProBioGen AG (Germany), Selexis SA (Germany), Sigma-Aldrich Co. LLC. (U.S.), Sony Biotechnology Inc. (U.S.), and Thermo Fisher Scientific Inc. (U.S.). Browse Full Report: http://www.transparencymarketresearch.com/biotherapeutics-cell-line- development-market.html About Us Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge. Contact Mr. Sudip S. 90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com